Last reviewed · How we verify

Pradaxa (Dabigatran etexilate) — Competitive Intelligence Brief

Pradaxa (Dabigatran etexilate) (Pradaxa (Dabigatran etexilate)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct thrombin inhibitor (anticoagulant). Area: Cardiovascular.

marketed Direct thrombin inhibitor (anticoagulant) Thrombin (Factor IIa) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Pradaxa (Dabigatran etexilate) (Pradaxa (Dabigatran etexilate)) — Bayer. Dabigatran etexilate is a direct thrombin inhibitor that blocks the final step of the coagulation cascade by directly binding to and inhibiting thrombin.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pradaxa (Dabigatran etexilate) TARGET Pradaxa (Dabigatran etexilate) Bayer marketed Direct thrombin inhibitor (anticoagulant) Thrombin (Factor IIa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct thrombin inhibitor (anticoagulant) class)

  1. Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pradaxa (Dabigatran etexilate) — Competitive Intelligence Brief. https://druglandscape.com/ci/pradaxa-dabigatran-etexilate. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: